A groundbreaking meta-analysis spearheaded by researchers at University College London (UCL) indicates that a single gene, APOE, may play a far more significant role in the development of Alzheimer’s disease than has been historically appreciated. The comprehensive study posits that an overwhelming majority, potentially exceeding 90%, of Alzheimer’s cases may not manifest in the absence of this particular gene’s influence. Beyond Alzheimer’s, the research also suggests a substantial contribution of APOE to the broader spectrum of dementia, with nearly half of all dementia diagnoses potentially linked to its activity. These findings, published in the esteemed journal npj Dementia, highlight APOE and the protein it encodes as a critical, yet often underestimated, target for future therapeutic interventions, potentially unlocking pathways to prevent or treat a considerable proportion of neurodegenerative conditions globally.
For decades, the scientific community has recognized a correlation between the APOE gene and Alzheimer’s disease. This gene exists in three primary common forms, or alleles: APOE2, APOE3, and APOE4. Each individual inherits two copies of the APOE gene, leading to six possible genetic combinations. Early research, dating back to the 1990s, established that individuals carrying one or two copies of the APOE4 allele face a markedly elevated risk of developing Alzheimer’s compared to those who inherit two copies of the APOE3 allele. Conversely, carriers of the APOE2 allele generally exhibit a lower risk than APOE3 carriers.
However, the recent UCL-led analysis suggests that the perceived impact of APOE, particularly the APOE3 allele, has been significantly understated. Dr. Dylan Williams, the study’s lead author from UCL’s Division of Psychiatry and Unit for Lifelong Health and Ageing, commented that the APOE gene’s contribution to the overall burden of Alzheimer’s disease has been long underestimated. While the APOE4 variant has been widely acknowledged by dementia researchers as detrimental, Dr. Williams pointed out that a substantial portion of the disease would not materialize without the additive effect of the APOE3 allele, which has traditionally been considered neutral regarding Alzheimer’s risk.
By considering the combined effects of both APOE3 and APOE4, the researchers propose that APOE’s involvement could be implicated in nearly all instances of Alzheimer’s disease. This suggests that if effective strategies could be developed to mitigate the risk conferred by both APOE3 and APOE4 variants, the majority of Alzheimer’s cases might be preventable.
This extensive modeling effort represents the most thorough attempt to date to quantify the population-level impact of common APOE variants on Alzheimer’s and broader dementia cases. The research team synthesized evidence connecting APOE3 and APOE4 to Alzheimer’s diagnoses, general dementia classifications, and the underlying pathological brain changes that precede clinical symptoms. A significant advantage of this analysis was the incorporation of data from four large-scale studies, encompassing over 450,000 participants. This extensive dataset enabled the researchers to identify a sufficiently large cohort of individuals with two APOE2 copies – a less common but low-risk group – who served as a crucial baseline for comparative analysis, a methodological approach not previously applied with such scope in similar studies.
Employing this robust methodology, the researchers projected that between 72% and 93% of Alzheimer’s cases might have been averted in the absence of the APOE3 and APOE4 variants. Furthermore, their conclusions indicated that approximately 45% of all dementia cases could be attributed to the influence of the APOE gene. These figures surpass previous estimations of APOE’s role, primarily because this analysis accounted for the impact of both APOE3 and APOE4, rather than concentrating solely on APOE4.
The variability observed across the included studies stemmed from differences in how Alzheimer’s and dementia were defined and assessed. This included variations in diagnostic criteria, whether diagnoses relied on medical records, other dementia classifications, or the detection of amyloid plaque buildup via brain imaging. Factors such as differing follow-up periods and participant recruitment strategies also contributed to these discrepancies. Nevertheless, the aggregated evidence strongly suggests that APOE is likely responsible for at least three-quarters of Alzheimer’s cases, and potentially more.
The implications of these findings are profound, advocating for APOE to be elevated as a higher priority in research focused on understanding disease mechanisms and developing novel therapeutic strategies. Dr. Williams emphasized that recent advancements in gene editing and other gene therapy modalities offer promising avenues for directly targeting genetic risk factors. Moreover, an understanding of genetic predispositions can illuminate physiological pathways that could be modulated by more conventional pharmacological approaches. Intervening directly on the APOE gene or the molecular cascade it influences could hold significant, and likely underappreciated, potential for preventing or treating a substantial proportion of Alzheimer’s disease. The extent to which APOE has been investigated as a target for drug development, he noted, has not been commensurate with its apparent importance.
Despite the potent influence of APOE, it is crucial to recognize that it is not the sole determinant of Alzheimer’s or other forms of dementia. Even among individuals with the highest genetic risk, such as those with two APOE4 copies, the lifetime risk of developing Alzheimer’s disease remains below 70%. Dr. Williams elaborated that most individuals carrying genetic risk factors like APOE3 and APOE4 will not develop dementia during a typical lifespan, owing to complex interactions with other genetic and environmental risk factors. Identifying the factors that modify the genetic risk inherited from APOE genes presents another critical challenge for dementia researchers.
For instance, other research has indicated that potentially half of dementia incidence could be prevented or delayed through improvements in numerous modifiable risk factors, such as addressing social isolation, managing high cholesterol, and discouraging smoking across populations. For complex conditions like Alzheimer’s and other causes of dementia, multiple pathways likely exist for risk reduction. Therefore, a multifaceted approach, exploring various strategies to modify Alzheimer’s and dementia risk, including but not limited to those targeting APOE, is warranted. Nevertheless, the fundamental observation remains that without the contributions of APOE3 and APOE4, the majority of Alzheimer’s disease cases would not manifest, irrespective of other inherited factors or life experiences of individuals carrying these variants.
This significant study was a collaborative effort between researchers at UCL and the University of Eastern Finland, with financial support provided by Alzheimer’s Research UK, the Medical Research Council, and other funding bodies. Dr. Sheona Scales, Director of Research at Alzheimer’s Research UK, underscored the study’s revelation that more Alzheimer’s cases are linked to the APOE gene than previously understood. However, she cautioned that not all individuals with these genetic variants will develop Alzheimer’s, underscoring the intricate interplay between genetics and other dementia risk factors. Despite APOE’s established link to Alzheimer’s, few treatments currently in clinical trials directly target this gene. The study’s findings, Dr. Scales added, highlight the importance of continued research into APOE for the development of future prevention and treatment strategies for Alzheimer’s. Alzheimer’s Research UK expressed its enthusiasm for supporting Dr. Williams’ ongoing investigations into how genetic factors, in conjunction with environmental and societal influences, impact dementia risk, a pursuit crucial for advancing towards a cure.
The elevated risk of dementia associated with APOE variants is thought to stem from several mechanisms. The APOE4 variant, for example, may increase dementia risk because the protein it produces is less efficient at clearing amyloid-beta, a sticky protein that aggregates to form plaques in the brain. It also appears to disrupt the brain cells’ ability to manage fats and energy and can promote inflammation, processes that may gradually damage neurons and heighten susceptibility to Alzheimer’s and related dementias. Further research is necessary to definitively confirm these pathways and to elucidate why APOE3 confers a higher dementia risk compared to APOE2.
About the Author
